Macular telangiectasia, often called MacTel, is a condition affecting the central part of the eye that gradually impacts a person’s ability to see fine details clearly. Understanding the available treatment approaches—both those currently used and those being tested in research—can help patients and their families navigate this challenging condition with greater confidence and realistic expectations.

Navigating Treatment Options for a Progressive Eye Condition

When someone receives a diagnosis of macular telangiectasia, particularly type 2, the first question often revolves around what can be done to preserve vision. The main goal of any treatment approach for MacTel is to slow down the disease’s progression and maintain quality of life for as long as possible. This means helping people keep their ability to read, drive, recognize faces, and perform other daily tasks that depend on clear central vision.^[1][2]

Treatment planning depends heavily on the stage of the disease and individual patient characteristics. In its earlier stages, when blood vessels are starting to change but vision loss remains mild, the approach differs from later stages when complications develop. Each person’s disease progresses at its own pace—some may experience gradual changes over many years, while others notice more rapid decline.^[4][5]

The landscape of MacTel treatment includes both established medical approaches approved by healthcare authorities and innovative therapies currently being explored through clinical research. For many years, doctors could only monitor patients and manage complications as they arose. However, scientific understanding has evolved considerably, particularly regarding what actually causes the disease. This shift in knowledge—from viewing MacTel primarily as a blood vessel problem to recognizing it as a condition where supportive cells in the retina malfunction—has opened doors to new treatment possibilities.^[4][11]

Standard Treatment Approaches for Macular Telangiectasia

For many years, there was no approved treatment specifically for the non-proliferative phase of MacTel type 2, which is the stage before new abnormal blood vessels form. During this phase, physicians typically focused on careful monitoring through regular eye examinations, including specialized imaging tests. This approach allowed doctors to track disease progression and watch for complications that might require intervention.^[11][13]

However, in March 2025, a groundbreaking approval changed the treatment landscape. The US Food and Drug Administration approved revakinagene taroretcel-lwey (marketed as Encelto), marking the first-ever approved treatment specifically for macular telangiectasia type 2. This represented a historic milestone after decades of having no approved therapeutic options for this progressive disease.^[9][10]

This newly approved treatment works quite differently from traditional medications. Instead of being a drug taken by mouth or injected repeatedly, it involves a tiny implant device, about the size of a grain of rice, that is surgically placed into the eye. The implant contains specially modified cells that continuously produce a protein called ciliary neurotrophic factor, or CNTF. This protein acts as a protective agent for the light-sensing cells in the retina, helping to preserve them over time.^[9][10][12]

The implant is anchored to the outer wall of the eye during a surgical procedure and can function for many years—potentially more than a decade—without needing replacement. The cells inside the device are enclosed within a semi-permeable membrane that allows the therapeutic protein to pass through into the eye while protecting the cells themselves. This technology, called encapsulated cell therapy, represents an entirely new approach to treating retinal diseases.^[10][12]

The approval was based on results from two major Phase 3 clinical trials. In these studies, patients who received the implant experienced significantly slower loss of their retinal photoreceptors—the specialized cells that detect light and enable vision. One study showed a 54.8% reduction in the rate of photoreceptor loss over two years compared to patients who received a sham treatment, while the other study demonstrated a 30.6% reduction. Additionally, patients who received the treatment showed improvements in reading speed and retinal sensitivity compared to those who did not.^[9][10]

When MacTel progresses to a stage where abnormal new blood vessels develop—called proliferative MacTel or subretinal neovascularization—a different treatment approach becomes necessary. This complication can cause sudden vision loss due to bleeding or fluid accumulation. For this stage, doctors use medications called anti-VEGF drugs, which are injected directly into the eye.^[11][13]

Anti-VEGF stands for “anti-vascular endothelial growth factor.” These medications work by blocking a chemical signal that promotes the growth of abnormal blood vessels. When these new vessels form, they tend to leak and bleed, causing damage to the retina. By preventing their growth and reducing leakage, anti-VEGF injections can help stabilize vision and prevent further deterioration. Multiple studies have shown that these injections provide significant structural and functional benefits when neovascularization occurs.^[11][21]

The anti-VEGF injections must be administered repeatedly, as their effect is temporary. Patients typically receive injections on a schedule determined by their doctor, based on how active the neovascularization is. The procedure itself takes just a few minutes and is performed in the doctor’s office, though the eye is numbed beforehand to minimize discomfort. Common side effects include temporary eye irritation, redness, or increased eye pressure, though serious complications are rare.^[11]

Other treatments have been tried over the years with limited success. Some doctors attempted using laser photocoagulation—a procedure that uses focused light to seal leaking blood vessels. However, this approach showed limited benefit and carried risks of causing additional retinal damage. Oral medications like acetazolamide, which reduces fluid accumulation, showed some structural improvements on imaging tests but did not lead to meaningful improvements in how well patients could see.^[11]

Some research has explored whether nutritional supplements, particularly carotenoids like lutein and zeaxanthin, might help slow MacTel progression. These substances are naturally found in the retina and play protective roles. However, studies testing carotenoid supplementation have produced mixed results, and there is not yet clear evidence that they significantly alter the disease course.^[11]

Promising Treatments Being Tested in Clinical Trials

Beyond the recently approved encapsulated cell therapy, researchers continue to investigate other innovative approaches to treating MacTel. Understanding these experimental treatments helps patients appreciate the ongoing efforts to find better ways to preserve vision and potentially halt disease progression entirely.^[2][11]

The encapsulated cell therapy delivering CNTF, now known as revakinagene taroretcel-lwey or NT-501, underwent extensive testing before its approval. Phase 1 trials focused on safety, establishing that the implant could be placed in the eye without causing unacceptable side effects. Phase 2 trials examined whether the treatment actually worked to slow disease progression and helped determine the best design for larger studies. The pivotal Phase 3 trials then compared the treatment directly against sham procedures in hundreds of patients at medical centers across multiple countries, including the United States, Europe, and Australia.^[2][9][10]

The mechanism of action behind CNTF therapy relates to the underlying cause of MacTel. Scientists now believe the disease primarily affects specialized cells called Müller cells, which provide structural and metabolic support to the retina. These cells normally produce CNTF, which protects photoreceptors from damage. When Müller cells malfunction or die in MacTel, CNTF levels drop, and photoreceptors begin to deteriorate. By providing a continuous external source of CNTF through the implant, the treatment compensates for this deficiency and helps preserve the remaining photoreceptors.^[4][23]

The cells used in the encapsulated device are derived from retinal pigment epithelium, a layer of cells that sits beneath the retina. These cells have been genetically modified to produce large amounts of CNTF. Because they are enclosed in a protective capsule, the patient’s immune system does not attack them, eliminating the need for immunosuppressive drugs. The capsule’s membrane allows nutrients to reach the cells and permits CNTF to exit while preventing other cells from entering.^[10][12]

Long-term follow-up studies of patients who received these implants have shown remarkable durability. Some implants have continued functioning and producing therapeutic levels of CNTF for more than ten years after placement. This longevity means patients potentially benefit from a single surgical procedure rather than requiring repeated treatments, which is a significant advantage over many other therapeutic approaches.^[10]

The MacTel Project, an international research initiative sponsored by the Lowy Medical Research Institute, has been instrumental in advancing understanding and treatment of this condition. This collaborative effort involves more than 60 medical centers worldwide and maintains a registry of MacTel patients. The project not only helped characterize the disease better but also facilitated clinical trials by connecting researchers with eligible patients. Patients enrolled in the registry contribute to research advancement and may have opportunities to participate in future clinical studies.^[2][22]

Research continues into other potential therapeutic approaches. Some scientists are investigating whether addressing metabolic abnormalities detected in MacTel patients might slow disease progression. Others are exploring additional neuroprotective factors beyond CNTF that might preserve retinal cells. Gene therapy approaches, which could potentially correct underlying cellular defects, remain an area of theoretical interest, though such treatments are not yet in active development for MacTel.^[11]

The encapsulated cell technology platform itself holds promise for treating other retinal diseases beyond MacTel. By modifying the cells to produce different therapeutic proteins, researchers could potentially address various conditions affecting the retina. This adaptability makes the technology platform particularly valuable for future drug development in ophthalmology.^[10][12]

Most Common Treatment Methods

• Encapsulated Cell Therapy (ECT)
  • First FDA-approved treatment specifically for macular telangiectasia type 2, approved in March 2025
  • Involves surgical implantation of a tiny device (the size of a rice grain) into the eye
  • Device contains genetically modified retinal pigment epithelium cells that continuously produce ciliary neurotrophic factor (CNTF)
  • CNTF acts as a neuroprotective protein that helps preserve photoreceptors in the retina
  • Implant can function for more than a decade without replacement
  • Phase 3 trials showed 30-55% reduction in photoreceptor loss over two years
  • Treatment slows disease progression but does not cure or reverse existing vision loss
• Anti-VEGF Therapy
  • Used specifically when abnormal new blood vessels develop (proliferative MacTel)
  • Medications are injected directly into the eye to block vascular endothelial growth factor
  • Prevents growth of abnormal blood vessels and reduces leakage that can damage the retina
  • Demonstrated significant structural and functional benefits for neovascularization
  • Requires repeated injections on a schedule determined by disease activity
  • Performed as an office procedure with local anesthesia
• Monitoring and Surveillance
  • Regular eye examinations with specialized imaging tests to track disease progression
  • Optical coherence tomography (OCT) used to measure retinal changes and photoreceptor loss
  • Fluorescein angiography helps visualize blood vessel abnormalities and leakage
  • Monitoring allows early detection of complications requiring intervention
  • Essential for determining appropriate timing for treatment interventions